Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt repayments

Daily Values

Growth Metrics

Plus Therapeutics (PSTV) Short-Term Debt repayments (2025)

Plus Therapeutics has reported Short-Term Debt repayments over the past 1 years, most recently at $3.3 million for Q1 2025.

Quarterly Short-Term Debt repayments changed N/A to $3.3 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $3.3 million for FY2025, N/A changed from the prior year.
Short-Term Debt repayments was $3.3 million for Q1 2025 at Plus Therapeutics.
Over five years, Short-Term Debt repayments peaked at $3.3 million in Q1 2025 and troughed at $3.3 million in Q1 2025.